Immunocastration using the Improvac vaccine offers a welfare-friendly alternative to surgical castration of male pigs. Understanding the science and barriers to adoption is important for improving pig welfare at scale.
Surgical castration without anaesthesia causes acute pain that is clearly visible in piglet behaviour - vocalisation, escape attempts, and post-operative distress. The scale of this practice - 80 million pigs annually in the EU - represents an enormous preventable welfare burden. Immunocastration eliminates the surgical wound and associated pain entirely while achieving the boar taint prevention goal. The welfare case for adoption is clear and unambiguous. The barrier is not scientific but commercial and consumer-related - some consumers have concerns about vaccine use that are not based on evidence of harm, and some markets have been slow to adopt the necessary consumer education. Policy frameworks that require pain relief for surgical castration accelerate the transition to immunocastration by reducing cost advantages of unanaesthetised surgery.